Can-Fite BioPharma Ltd.CANF

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE American · Israel · canfite.com

Can-Fite BioPharma Ltd. is an advanced clinical-stage drug development company with a platform technology targeting cancer, liver and inflammatory disease. Its lead candidate Piclidenoson is in a pivotal Phase 3 trial for psoriasis; its liver drug Namodenoson is in Phase 3 for hepatocellular carcinoma, Phase 2b for MASH and Phase 2a in pancreatic cancer. A third candidate, CF602, targets erectile dysfunction.

Key ratios

FCF / Sales

-2348.9%TTM

2025 -2210.1%2024 -1133.8%2023 -1136.2%

ROA

-77.1%TTM

2025 -66.8%2024 -53.2%2023 -53.2%

ROE

-211.4%TTM

2025 -178.2%2024 -134.9%2023 -142.5%

Revenue growth

-27.7%TTM

2025 -39.9%2024 -9.3%2023 -8.3%

Recent news

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study 2026-09-02 · GlobeNewswire

Track CANF in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer